Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

35.28
-0.6900-1.92%
Post-market: 35.25-0.0333-0.09%17:09 EST
Volume:1.39M
Turnover:48.57M
Market Cap:3.75B
PE:43.02
High:35.73
Open:34.92
Low:34.00
Close:35.97
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.76
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:5.79
PE(LYR):43.02

Loading ...

BRIEF-Corcept Therapeutics Q3 EPS USD 0.16

Reuters
·
Nov 05, 2025

Corcept Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview

Reuters
·
Nov 01, 2025

Corcept Therapeutics Incorporated to announce third quarter financial results

Reuters
·
Oct 29, 2025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

THOMSON REUTERS
·
Oct 29, 2025

Corcept Therapeutics (CORT) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Oct 21, 2025

Corcept Therapeutics (CORT) Is Up 9.9% After Relacorilant–Nab-Paclitaxel Phase 3 Success in Ovarian Cancer

Simply Wall St.
·
Oct 21, 2025

Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20, 2025

Promising Potential of Corcept Therapeutics’ Relacorilant in Ovarian Cancer Treatment Drives Buy Rating

TIPRANKS
·
Oct 20, 2025

Truist Financial Sticks to Its Buy Rating for Corcept Therapeutics (CORT)

TIPRANKS
·
Oct 20, 2025

Corcept Therapeutics Reports Positive Phase 3 Results for Relacorilant in Platinum-Resistant Ovarian Cancer

Reuters
·
Oct 19, 2025

Canaccord Genuity Keeps Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
Oct 16, 2025

Corcept Therapeutics Director Daniel N. Swisher, Jr. Reports Disposal of Common Shares

Reuters
·
Oct 16, 2025

Corcept submits relacorilant marketing authorization application to EMA

TIPRANKS
·
Oct 14, 2025

Corcept Therapeutics Submits Marketing Authorization Application to EMA for Relacorilant in Platinum-Resistant Ovarian Cancer; FDA Review Ongoing

Reuters
·
Oct 14, 2025

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Oct 14, 2025

BRIEF-Corcept Therapeutics Inc - Terminates Distribution Agreement With Optime Care - SEC Filing

Reuters
·
Oct 14, 2025

Corcept Therapeutics to Terminate Distribution Services Agreement with Optime Care Effective January 2026

Reuters
·
Oct 14, 2025

Corcept lower after Optime Care terminates distributor agreement for Korlym

TIPRANKS
·
Oct 10, 2025

Corcept Therapeutics falls -15.0%

TIPRANKS
·
Oct 10, 2025

Truist Financial Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
Oct 10, 2025